Helix Biopharma Corp.
HBPCF
$1.71
-$0.02-1.16%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.27% | -44.98% | -36.57% | -45.02% | 222.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.16% | -59.22% | -52.04% | -42.94% | 54.53% |
| Operating Income | 66.16% | 59.22% | 52.04% | 42.94% | -54.53% |
| Income Before Tax | 64.86% | 57.82% | 49.31% | 45.19% | -51.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.86% | 57.82% | 49.31% | 45.19% | -51.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.86% | 57.82% | 49.31% | 45.19% | -51.20% |
| EBIT | 66.16% | 59.22% | 52.04% | 42.94% | -54.53% |
| EBITDA | 66.16% | 59.24% | 52.05% | 42.96% | -54.72% |
| EPS Basic | 75.69% | 67.82% | 58.13% | 51.36% | -21.99% |
| Normalized Basic EPS | 75.75% | 67.92% | 58.03% | 51.28% | -22.01% |
| EPS Diluted | 75.69% | 67.82% | 58.13% | 51.36% | -21.99% |
| Normalized Diluted EPS | 75.75% | 67.92% | 58.03% | 51.28% | -22.01% |
| Average Basic Shares Outstanding | 46.64% | 42.47% | 34.51% | 24.38% | 22.20% |
| Average Diluted Shares Outstanding | 46.64% | 42.47% | 34.51% | 24.38% | 22.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |